Laura DeForge, Sr Scientist at Genentech to speak at 5th Assay Conference Sept 20-21, 2010 San Diego

June 22, 2010 - PRLog -- SAN DIEGO, CA Laura DeForge, Senior Scientist at Genentech, Inc, to speak at GTCbio’s 5th Assay and Drug Discovery Technologies on Sept. 20-21, 2010 in San Diego, CA.  

Laura DeForge will give a presentation on “Real-time Impedance-based Bioassays Using the xCELLigence™ Technology.” at 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio.  xCELLigence is a cell-based assay platform that allows for real-time, label-free monitoring of cellular responses by measuring electrical impedance.  Benefits of xCELLigence include: Real-time data collection over the course of the experiment yields more information than endpoint assays, the readout is label free and does not interfere with cell growth or response, and assay development is rapid, with minimal hands-on time with simple operation

Laura DeForge received her Ph.D. in Pharmacology from the University of Michigan and did her post-doctoral training in cytokine biology in the Department of Pathology, also at the University of Michigan. After working on novel approaches to inhibiting cytokine production at a start-up company, Laura joined Genentech in 1994, first in the Development organization, and then moved to the Assay & Automation Technology (AAT) Department in Research in 1997. She currently leads her group to develop a broad range of assay types, including quantitative immunoassays, anti-therapeutic antibody assays, immunochemical and cell-based binding assays, activity indicating cell-based and enzymatic potency assays, and multiplexed assays using various technologies. Most of her work currently focuses on antibody therapeutics for immunology indications.  

Also presenting at the Assay and Drug Discovery Technologies are prestigious organizations including Burnham Medical Research Institute, Pfizer, UCSF, AstraZeneca, UCLA, Bristol Myers Squibb, Genentech, National Institute of Advanced Science and Technology, Johnson & Johnson, Nexigen GmbH, University of Pennsylvania, Roche, UCD, Abbott, Merck, Novartis (GNF), and other leaders in the Assay and Drug Discovery Technologies industry.

5th Assay and Drug Discovery Technologies Conference  features a mixture of academic, industry and public sector experts in an intimate setting that favors the showcase of data, the exchanges of ideas and networking.  Professionals in the drug discovery industry and academics to can get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output. For more information, visit www.gtcbio.com.